évolis® certified Australian made and tested to the highest quality standards to ensure the quality of each product.
1: THE FORMULATION OF ÉVOLIS® SIGNIFICANTLY LENGTHENS THE HAIR GROWTH PHASE (ANAGEN), DECREASES HAIR FALL AND INCREASES HAIR DENSITY.
PROMOTION OF ANAGEN, INCREASED HAIR DENSITY AND REDUCTION OF HAIR FALL IN A CLINICAL SETTING FOLLOWING IDENTIFICATION OF FGF5-INHIBITING COMPOUNDS VIA A NOVEL 2-STAGE PROCESS
DOMINIC BURG (Cellmid Ltd. & Advangen International), MASKUNI YAMAMOTO (Advangen Inc.), MASATO NAMEKATA(Advangen Inc.), JOSEPH HAKLANI (Cellmid Ltd. & Advangen International), KOICHIRO KOIKE(Advangen Inc.), AND MARIA HALASZ (Cellmid Ltd. & Advangen International)
Clinical, Cosmetic and Investigational Dermatology. 10: 71-85. 27 Feb 2017
- A new Single molecule FGF5 inhibitor was discovered. The molecule was seven times more potent (p<0.005) than previously identified crude plant extracts. A significant improvement in potency and precision.
- After 112 days (16 weeks) of treatment, Participants using évolis® containing the new FGF5 inhibitor had:
- 44.2% increase in the number of anagen follicles (p=0.002)
- All but one participant improved in visual grading (p=0.002)
- 82.1% less hair fall (p=0.007)
This scientific publication describes the development and screening programme behind the Company’s FGF5 inhibitory technology and the discovery of novel, single molecule FGF5 inhibitors. The paper also describes the results of the blinded, placebo controlled clinical study of topical formulations containing the lead inhibitor in men and women. The paper can be accessed via the Journal website or via the scientific journal indexing site PubMed.
Advangen’s scientists discovered potent FGF5 inhibitory activity amongst select members of the monoterpene family with the lead molecule MTP3 nearly seven times more potent than the company’s previously published inhibitors (p=0.0024).
A panel of 32 healthy individuals with hair loss (Male: Hamilton Norwood scale 2 to 4, and Women: Ludwig scale i2 toii2) were randomised into 3 age and sex matched groups: Placebo, and two formulations with differing concentrations of novel active. Participants were assessed over 16 weeks of treatment by measuring hair fall, anagen-telogen ratio (the ratio of hairs in growth phase compared to those in rest phase), expert visual grading, and a subset was examined by high resolution matched photography.
Both formulations showed significant improvements over baseline and compared to placebo. The best performing formulation was able to increase the number of follicles in the growth phase by an average of 44% (p=0.002), reduce hair loss by 81% (p=0.007), and improve the appearance on visual grading in all but one participant (p=0.004). A subset of participants displayed a continued increase in hair density on digitally matched photography over the 16-week study period. (p=0.03) Direct comparison to placebo showed that the treated groups performed better than placebo in visual grading (p=0.0005) and hair fall (p=0.002). The Placebo group did not show any improvement and had a trend for worsening hair-fall over 16 weeks.
2: THE BOTANICAL EXTRACT, SANGUISORBA OFFICINALIS, ACCELERATES HAIR GROWTH BY 18%
SANGUISORBA OFFICINALIS ROOT EXTRACT HAS FGF5 INHIBITORY ACTIVITY AND REDUCES HAIR LOSS BY CAUSING PROLONGATION OF THE ANAGEN PERIOD
MAEDA TETSUO (POLA Chemical Ind., Inc., JPN) YAMAMOTO TAKUYA (POLA Chemical Ind., Inc., JPN) ISHIKAWA YOKO (POLA Chemical Ind., Inc., JPN) ITO NORIIE (Advangen, Inc., JPN) ARASE SEIJI (Univ. Tokushima, Graduate School, Inst. Health Biosciences, JPN)
Nishinihon Journal of Dermatology 69(1): 81-86
In a clinical study using 39 volunteers with hair loss, Sanguisorba Officinalis (SO) significantly decreased the telogen/anagen hair ratio and the number of shed hairs. Furthermore, topical application of SO extract on the scalp significantly elevated the growth rate of hair by 18% over a four-month period. These findings suggest that FGF5-antagonizing activity of SO extract observed in vitro is closely related to its clinical effects.
3: FGF5 SIGNALS HAIR TO STOP GROWING
CLAIRE A. HIGGINS (Columbia Univ., NY, USA) LYNN PETUKHOVA (Columbia Univ., NY, USA) SIVAN HAREL (Columbia Univ., NY, USA) YUAN Y. HO(Columbia Univ., NY, USA) ESTHER DRILL (Columbia Univ., NY,USA) LAWRENCE SHAPIRO (Columbia Univ., NY, USA) MUHAMMAD WAJID(Columbia Univ., NY, USA and Univ. of Education, PAK) ANGELAM. CHRISTIANO (Columbia Univ., NY, USA)
Proc Natl Acad Sci U S A. 111(29):10648-53
Mechanisms that regulate the growth of eyelashes have remained obscure. Higgins et al ascertained two families from Pakistan who presented with familial trichomegaly, or extreme eyelash growth. Using a combination of whole exome sequencing and homozygosity mapping, they have identified distinct pathogenic mutations within fibroblast growth factor 5 (FGF5) that underlie the disorder. Subsequent sequencing of this gene in several additional trichomegaly families identified an additional mutation in FGF5. They further demonstrated that hair fibres from forearms of these patients were significantly longer than hairs from control individuals, with an increased proportion in the growth phase, anagen. Using hair follicle organ cultures, they show in this study that FGF5 induces regression of the human hair follicle. They have identified FGF5 as a crucial regulator of hair growth in humans for the first time, and uncovered a therapeutic target to selectively regulate eyelash growth.
4: The breakthrough FGF5 technology used in évolis® represents a radical new way to treat hair loss.
Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness
Stefanie Heilmann-Heimbach1,2,*, Christine Herold3,*, Lara M. Hochfeld1,2, Markus M. Nothen1,2,* et al.
NATURE COMMUNICATIONS | 8:14694 | DOI: 10.1038/ncomms14694|www.nature.com/naturecommunications
Male-pattern baldness (MPB) is a common and highly heritable trait characterized by androgen-dependent, progressive hair loss from the scalp. Here, we carry out the largest GWAS meta-analysis of MPB to date, comprising 10,846 early-onset cases and 11,672 controls from eight independent cohorts. We identify 63 MPB-associated loci (Po5_10_8, METAL) of which 23 have not been reported previously. The 63 loci explain B39% of the phenotypic variance in MPB and highlight several plausible candidate genes (FGF5, IRF4, DKK2) and pathways (melatonin signalling, adipogenesis) that are likely to be implicated in the key-pathophysiological features of MPB and may represent promising targets for the development of novel therapeutic options. The data provide molecular evidence that rather than being an isolated trait, MPB shares a substantial biological basis with numerous other human phenotypes and may deserve evaluation as an early prognostic marker, for example, for prostate cancer, sudden cardiac arrest and neurodegenerative disorders.